<DOC>
	<DOC>NCT00392925</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, and effect on body weight of leptin, injected subcutaneously, in combination with pramlintide, injected subcutaneously.</brief_summary>
	<brief_title>A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<criteria>Is obese (Body Mass Index [BMI]&gt;=30kg/m^2 and &lt;=35kg/m^2); or overweight (BMI&gt;=27kg/m^2 and &lt;30kg/m^2) with abdominal obesity, based on the following: *waist circumference &gt;102 cm if male, *waist circumference &gt;88 cm if female Is a nonsmoker (has not smoked for at least 6 months prior to the study) Consumes a morning and evening meal each day Is diagnosed with type 2 diabetes Is currently enrolled or plans to enroll in a diet, weight loss, or exercise program with the specific intent of losing weight (subjects who have been following an exercise regimen resulting in stable weight maintenance for at least 2 months prior to enrollment are eligible for study inclusion) Has been treated over the past 2 months, is currently treated, or is expected to require or undergo treatment with any of the following medications: *antiobesity agents (prescription or overthecounter), *antipsychotic agents, *antiepileptic agents, *antidepressant agents, *drugs that directly affect gastrointestinal motility Has received any investigational drug within 30 days or within a period corresponding to 5 halflives of that drug, whichever is greater, prior to this study starting Has previously received treatment with recombinant leptin or pramlintide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>overweight</keyword>
	<keyword>obesity</keyword>
	<keyword>pramlintide</keyword>
	<keyword>leptin</keyword>
	<keyword>Amylin</keyword>
</DOC>